- Report
- May 2026
- 330 Pages
Global
From €2601EUR$2,800USD£2,176GBP
- Report
- September 2026
- 310 Pages
Global
From €3878EUR$4,175USD£3,244GBP
- Report
- March 2026
- 320 Pages
Global
From €3855EUR$4,150USD£3,225GBP
- Report
- September 2026
- 183 Pages
Global
From €3293EUR$3,545USD£2,755GBP
€3659EUR$3,939USD£3,061GBP
- Report
- September 2026
- 190 Pages
Global
From €3293EUR$3,545USD£2,755GBP
€3659EUR$3,939USD£3,061GBP
- Report
- September 2026
- 189 Pages
Global
From €3293EUR$3,545USD£2,755GBP
€3659EUR$3,939USD£3,061GBP
- Report
- September 2026
- 186 Pages
Global
From €3293EUR$3,545USD£2,755GBP
€3659EUR$3,939USD£3,061GBP
- Report
- September 2026
- 192 Pages
Global
From €3293EUR$3,545USD£2,755GBP
€3659EUR$3,939USD£3,061GBP
- Report
- September 2026
- 186 Pages
Global
From €3293EUR$3,545USD£2,755GBP
€3659EUR$3,939USD£3,061GBP
- Report
- September 2026
- 186 Pages
Global
From €3293EUR$3,545USD£2,755GBP
€3659EUR$3,939USD£3,061GBP
- Report
- February 2026
- 250 Pages
Global
From €4171EUR$4,490USD£3,489GBP
- Report
- October 2026
- 182 Pages
Global
From €5434EUR$5,850USD£4,546GBP
- Report
- October 2026
- 193 Pages
Global
From €5434EUR$5,850USD£4,546GBP
- Report
- October 2026
- 246 Pages
Global
From €5434EUR$5,850USD£4,546GBP
- Report
- October 2026
- 190 Pages
Global
From €5434EUR$5,850USD£4,546GBP
- Report
- October 2026
- 126 Pages
Global
From €5434EUR$5,850USD£4,546GBP
- Report
- October 2026
- 183 Pages
Global
From €5434EUR$5,850USD£4,546GBP
- Report
- October 2026
- 198 Pages
Global
From €5434EUR$5,850USD£4,546GBP
- Report
- October 2026
- 391 Pages
Global
From €5434EUR$5,850USD£4,546GBP
- Report
- October 2026
- 183 Pages
Global
From €5434EUR$5,850USD£4,546GBP

Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers.
Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated.
Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more